Last reviewed · How we verify

Dipeptamin — Competitive Intelligence Brief

Dipeptamin (ALANYL GLUTAMINE) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: alanyl glutamine. Area: Other.

phase 3 alanyl glutamine Other Small molecule Live · refreshed every 30 min

Target snapshot

Dipeptamin (ALANYL GLUTAMINE). Dipeptamin works by providing the body with a building block of protein, specifically the amino acids alanine and glutamine.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Dipeptamin TARGET ALANYL GLUTAMINE phase 3 alanyl glutamine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (alanyl glutamine class)

  1. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dipeptamin — Competitive Intelligence Brief. https://druglandscape.com/ci/alanyl-glutamine. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing